In an exclusive interview, Sanofi's head of oncology development Joanne Lager explains how the French big pharma could make a comeback in cancer this year and highlights its immunotherapy combination opportunities.
Sanofi will make key regulatory submissions in 2018 aimed at bringing its immuno-oncology portfolio up to speed; the company's head of oncology development Joanne Lager tells Scrip about the company's PD-1 strategy and promising early-stage R&D candidates.
Sanofi is not a top player in the IO market, having fallen behind the likes of Merck & Co....
Create an account to read this article
Already a subscriber?
Cardiologists know PCSK9 inhibition is a powerful LDL-lowering tool and now Amgen’s VESALIUS data show it may be worth adding to the primary care physician’s toolbox for prevention of high-risk patients’ first major cardiovascular events.
The FDA approved the anti-CD38 monoclonal antibody, a mainstay of multiple myeloma for a decade, for high-risk smoldering disease.
Even with Innosera's sweetened offers and a boardroom recommendation, the proposed acquisition could not clear the minimum 66.67% shareholder approval level.
Do US FDA’s efforts at simplifying the biosimilar pathway create more competition and threaten Aurobindo Pharma's return on investments? Management speaks on this, biosimilar filing plans and deal strategy at the Q2 FY26 earnings call
Do US FDA’s efforts at simplifying the biosimilar pathway create more competition and threaten Aurobindo Pharma's return on investments? Management speaks on this, biosimilar filing plans and deal strategy at the Q2 FY26 earnings call
South Korea’s two biosimilars giants have laid out differing strategies to pursue innovative drug R&D, although both are positioning ADCs as a core focus.
Another strong quarter keeps AstraZeneca on track to meet its $80bn sales ambition, and its CEO maintains the recent Trump deal provides pricing reassurance, despite a lack of details so far.
